title: Studies on fMLP-receptor interaction and signal transduction pathway by means of fMLP-OMe selective analogues.
abstract: For-Thp-Leu-Ain-OMe ([Thp(1), Ain(3)] fMLP-OMe) (2), for-Met-delta(z)Leu-Phe-OMe ([delta(z)Leu(2)] fMLP-OMe) (3), for-Thp-Leu-Phe-OMe ([Thp(1)] fMLP-OMe) (4), and for-Met-Leu-Ain-OMe ([Ain(3)] fMLP-OMe) (5) are for-Met-Leu-Phe-OMe (fMLP-OMe) (1) analogues which discriminate between different responses of human neutrophils. Peptides 3 and 5, similar to fMLP-OMe, enhance neutrophil cyclic AMP (cAMP) as well as calcium levels, while analogues 2 and 4, which evoke only chemotaxis, do not alter the concentration of these intracellular messengers. When we tested the peptides' ability to displace [3H]-fMLP from its binding sites, the following order of potency was observed: analogue 1 > 3 > 5 > 2 > 4. A particularly low activity at the receptor level characterized analogues 2 and 4. Their low effectiveness was not improved by the addition of cytochalasin B, by different incubation temperatures, or by the absence of endogenous guanine nucleotides, conditions known to influence fMLP receptor fate and functionality. We speculate that, in certain conditions, the fMLP receptor may undergo conformational changes that impede the binding of pure chemoattractants.
authors.affiliation: Dipartimento di Biologia, via Selmi 3, Università di Bologna, 40100 Bologna, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Fabbri
authors.forename: S
authors.initials: S
authors.lastname: Spisani
authors.forename: L
authors.initials: L
authors.lastname: Barbin
authors.forename: C
authors.initials: C
authors.lastname: Biondi
authors.forename: M
authors.initials: M
authors.lastname: Buzzi
authors.forename: S
authors.initials: S
authors.lastname: Traniello
authors.forename: G P
authors.initials: GP
authors.lastname: Zecchini
authors.forename: M E
authors.initials: ME
authors.lastname: Ferretti
mesh_terms: D020013:Calcium Signaling / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D000242:Cyclic AMP / Q000096:biosynthesis; D003571:Cytochalasin B / Q000494:pharmacology; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D006801:Humans; D008024:Ligands; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects*; D044042:Receptors, Formyl Peptide; D011971:Receptors, Immunologic / Q000187:drug effects*; D018000:Receptors, Peptide / Q000187:drug effects*; D015290:Second Messenger Systems / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects*; D013696:Temperature
chemical_list: D008024:Ligands; D044042:Receptors, Formyl Peptide; D011971:Receptors, Immunologic; D018000:Receptors, Peptide; C415595:formyl-4-aminotetrahydrothiopyran-4-carbonyl-leucyl-phenylalanine methyl ester; C109944:formyl-Thp-leucyl-Ain-methyl ester; C415596:formyl-methionyl-2,3-didehydroleucyl-phenylalanine methyl ester; C415594:formyl-methionyl-leucyl-2-aminoindane-2-carboxylic acid methyl ester; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D003571:Cytochalasin B; D009240:N-Formylmethionine Leucyl-Phenylalanine; D000242:Cyclic AMP